Jump to content

Tadamitsu Kishimoto: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
removed Category:Immunologists using HotCat – redundant
 
(35 intermediate revisions by 28 users not shown)
Line 1: Line 1:
{{short description|Japanese immunologist (born 1939)}}
{{Infobox scientist
{{Infobox scientist
|name = Tadamitsu Kishimoto
|name = Tadamitsu Kishimoto
Line 4: Line 5:
|image_size = 200px
|image_size = 200px
|caption =
|caption =
|birth_date = {{Birth date|1939|05|07}} (age 76)
|birth_date = {{Birth date|1939|05|07}} (age 84)
|death_date =
|death_date =
|birth_place = [[Osaka]], [[Japan]]
|birth_place = [[Tondabayashi, Osaka]], [[Japan]]
|nationality = {{flag|Japan}}
|nationality = {{flag|Japan}}
|alma_mater = [[Osaka University]]
|alma_mater = [[Osaka University]]
Line 12: Line 13:
|known_for =
|known_for =
| notable_students =
| notable_students =
|prizes = {{no wrap|[[Asahi Prize]] {{small|(1988)}}<br>[[Imperial Prize of the Japan Academy]] {{small|(1992)}}<br>[[Order of Culture]] {{small|(1998)}}<br>[[Robert Koch Gold Medal]] {{small|(2003)}}<br>[[Crafoord Award]] {{small|(2009)}}}}
|prizes = {{no wrap|[[Asahi Prize]] {{small|(1988)}}<br>[[Imperial Prize of the Japan Academy]] {{small|(1992)}}<br>[[Order of Culture]] {{small|(1998)}}<br>[[Robert Koch Gold Medal]] {{small|(2003)}}<br>[[Crafoord Prize]] {{small|(2009)}}<br>[[King Faisal International Prize]]{{small|(2017)}}<br>[[Tang Prize]] {{small|(2020)}}}}
}}
}}
Dr.{{nihongo|'''Tadamitsu Kishimoto'''|岸本 忠三|Kishimoto Tadamitsu|extra=born May 7, 1939 in [[Osaka]]}} is a Japanese [[immunologist]] known for research on [[IgM]] and [[cytokines]], most famously, [[interleukin 6]].
{{nihongo|'''Tadamitsu Kishimoto'''|岸本 忠三|Kishimoto Tadamitsu|extra=born May 7, 1939 in [[Tondabayashi, Osaka]]}} is a Japanese [[immunologist]] known for research on [[IgM]] and [[cytokines]], most famously, [[interleukin 6]].


He did postdoctoral work under [[Kimishige Ishizaka]], the discoverer of [[IgE]] at [[Johns Hopkins University]].
He did postdoctoral work under [[Kimishige Ishizaka]], the discoverer of [[IgE]] at [[Johns Hopkins University]].
Line 23: Line 24:
Tadamitsu Kishimoto, who was born in [[Osaka]] in 1939, was President of [[Osaka University]] from 1997 to 2003 and a Member, Council for Science and Technology Policy, Cabinet office from 2004 to 2006. He is now Professor, Graduate School of Frontier Biosciences, Osaka University. He was Dean, Professor and Chairman of Department of Medicine at Osaka University Medical School from which he graduated in 1964.<ref name="japanprize">http://www.japanprize.jp/en/prize_prof_2011_kishimoto.html, The Japan Prize Foundation</ref> He is currently Japan's leading scientist in the field of life science, specifically in immunology and has made fundamental contributions to the understanding of cytokine functions through series of his studies on IL-6, its receptor system, and transcription factors. He has developed anti-IL6 receptor therapy for several immune disorders including [[Castleman's disease]], [[rheumatoid arthritis]] and [[juvenile idiopathic arthritis]].
Tadamitsu Kishimoto, who was born in [[Osaka]] in 1939, was President of [[Osaka University]] from 1997 to 2003 and a Member, Council for Science and Technology Policy, Cabinet office from 2004 to 2006. He is now Professor, Graduate School of Frontier Biosciences, Osaka University. He was Dean, Professor and Chairman of Department of Medicine at Osaka University Medical School from which he graduated in 1964.<ref name="japanprize">http://www.japanprize.jp/en/prize_prof_2011_kishimoto.html, The Japan Prize Foundation</ref> He is currently Japan's leading scientist in the field of life science, specifically in immunology and has made fundamental contributions to the understanding of cytokine functions through series of his studies on IL-6, its receptor system, and transcription factors. He has developed anti-IL6 receptor therapy for several immune disorders including [[Castleman's disease]], [[rheumatoid arthritis]] and [[juvenile idiopathic arthritis]].


He has received numerous awards, including the [[Imperial Prize of the Japan Academy]] in 1992,<ref name="japanprize"/> the Sandoz Prize for Immunology from the International Union of Immunological Society in 1992<ref name="japanprize"/> and the Avery-Landsteiner Prize from the German Immunology Society in 1996.<ref name="japanprize"/> In 1998, he was awarded the [[Order of Culture]] from Emperor.<ref name="japanprize"/> He was awarded [[Robert Koch Gold Medal]] in 2003,<ref name="japanprize"/> Honorary Life Time Achievement Awards from International Cytokine Society in 2006<ref name="japanprize"/> and the [[Crafoord Award]] from the Royal Swedish Academy of Sciences in 2009.<ref name="japanprize"/> He has been elected a Foreign Associate of the US National Academy of Sciences in 1991,<ref name="japanprize"/> a member of the Japan Academy in 1995<ref name="japanprize"/> and a member of Deutsche Akademine der Naturforscher Leopoldina in 2005.<ref name="japanprize"/> He served as a president of the International Immunopharmacology Society, International Cytokine Society and the Japanese Immunology Society. He is an honorary member in American Association of Immunologists and American Society of Hematology.
He has received numerous awards, including the [[Imperial Prize of the Japan Academy]] in 1992,<ref name="japanprize"/> the Sandoz Prize for Immunology from the International Union of Immunological Society in 1992<ref name="japanprize"/> and the Avery-Landsteiner Prize from the German Immunology Society in 1996.<ref name="japanprize"/> In 1998, he was awarded the [[Order of Culture]] from Emperor.<ref name="japanprize"/> He was awarded [[Robert Koch Gold Medal]] in 2003,<ref name="japanprize"/> Honorary Life Time Achievement Awards from International Cytokine Society in 2006<ref name="japanprize"/> and the [[Crafoord Award]] from the Royal Swedish Academy of Sciences in 2009.<ref name="japanprize"/> He has been elected a Foreign Associate of the US National Academy of Sciences in 1991,<ref name="japanprize"/> a member of the Japan Academy in 1995<ref name="japanprize"/> and a member of [[German Academy of Sciences Leopoldina]] in 2005.<ref name="japanprize"/> He served as a president of the International Immunopharmacology Society, International Cytokine Society and the Japanese Immunology Society. He is an honorary member in American Association of Immunologists and American Society of Hematology. In 2020, He received the prestigious Tang Prize in Biopharmaceutical Science.


==IL-6==
==IL-6==
In the early 1970s, Dr. Kishimoto discovered the activity inducing antibody production in culture supernatants of [[T cell]]s. Furthermore, he demonstrated that the activity for inducing IgG and IgE antibodies could be separated.<ref>Kishimoto, T., and K. Ishizaka. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194-1205, 1973.</ref> Later, this finding led to the discovery of the dichotomy of helper T cells, Th1 and Th2.
In the early 1970s, Kishimoto discovered the activity inducing antibody production in culture supernatants of [[T cell]]s. Furthermore, he demonstrated that the activity for inducing IgG and IgE antibodies could be separated.<ref>Kishimoto, T., and K. Ishizaka. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194-1205, 1973.</ref> Later, this finding led to the discovery of the dichotomy of helper T cells, Th1 and Th2.
On the basis of these early studies, Dr. Kishimoto discovered and cloned interleukin-6 and its receptor and delineated the signaling pathway used by IL-6 and the set of related cytokines that utilize gp-130, which he also discovered.<ref>Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.</ref><ref>Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.</ref><ref>Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. Cloning and expression of human interleukin 6 (BSF-2/IFNb2) receptor. Science 241:825-828, 1988.</ref><ref>Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.</ref> He identified the transcription factors [[NF-IL-6]] and [[STAT3]], both central to the action of IL-6.<ref>Akira, S., Y.Nishio, M.Inoue, X.Wang, S.Wei, T.Matsusaka, K.Yoshida, T.Sudo, M.Naruto, and T.Kishimoto. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.</ref> He further discovered a family of suppressors of cytokine signaling, the SOCS molecules, that are key regulators of cytokine function.<ref>Naka, T., M. Narazaki, M.Hirata, T.Matsumoto, S.Minamoto, A.Aono, N.Nishimoto, T.Kajita, T.Taga, K.Yoshizaki, S.Akira, and T.Kishimoto. Structure and function of a new STAT-induced STAT inhibitor-1. Nature 387:924-929, 1997.</ref>
On the basis of these early studies, Kishimoto discovered and cloned interleukin-6 and its receptor and delineated the signaling pathway used by IL-6 and the set of related cytokines that utilize gp-130, which he also discovered.<ref>Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.</ref><ref>Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.</ref><ref>Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. Cloning and expression of human interleukin 6 (BSF-2/IFNb2) receptor. Science 241:825-828, 1988.</ref><ref>Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.</ref> He identified the transcription factors [[NF-IL-6]] and [[STAT3]], both central to the action of IL-6.<ref>Akira, S., Y.Nishio, M.Inoue, X.Wang, S.Wei, T.Matsusaka, K.Yoshida, T.Sudo, M.Naruto, and T.Kishimoto. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.</ref> He further discovered a family of suppressors of cytokine signaling, the SOCS molecules, that are key regulators of cytokine function.<ref>Naka, T., M. Narazaki, M.Hirata, T.Matsumoto, S.Minamoto, A.Aono, N.Nishimoto, T.Kajita, T.Taga, K.Yoshizaki, S.Akira, and T.Kishimoto. Structure and function of a new STAT-induced STAT inhibitor-1. Nature 387:924-929, 1997.</ref>
He demonstrated the involvement of IL-6 in the pathogenesis of [[cardiac myxoma]]s, [[multiple myeloma]], Castleman’s disease, rheumatoid arthritis, [[Crohn's disease]] and juvenile idiopathic arthritis (JIA). He identified IL-6 as a [[hepatocyte stimulating factor]] which induces acute phase reactions.
He demonstrated the involvement of IL-6 in the pathogenesis of [[cardiac myxoma]]s, [[multiple myeloma]], Castleman’s disease, rheumatoid arthritis, [[Crohn's disease]] and juvenile idiopathic arthritis (JIA). He identified IL-6 as a [[hepatocyte stimulating factor]] which induces acute phase reactions.
He prepared a monoclonal anti-IL-6 receptor antibody that was subsequently humanized and has been shown to be of great therapeutic value in a series of autoinflammatory diseases including Castleman's Disease, rheumatoid arthritis and juvenile idiopathic arthritis.<ref>Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, T. Kishimoto. Efficary and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008</ref>
He prepared a monoclonal anti-IL-6 receptor antibody that was subsequently humanized and has been shown to be of great therapeutic value in a series of autoinflammatory diseases including Castleman's Disease, rheumatoid arthritis and juvenile idiopathic arthritis.<ref>Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, T. Kishimoto. Efficary and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008</ref>
Line 33: Line 34:
A series of his IL-6 studies for 35 years since 1973 have been highly appreciated; He was ranked as the world’s 8th-most-cited researchers between 1983 and 2002 and he is in the top ten of h-index of living biologists.
A series of his IL-6 studies for 35 years since 1973 have been highly appreciated; He was ranked as the world’s 8th-most-cited researchers between 1983 and 2002 and he is in the top ten of h-index of living biologists.


==Recognition==
⚫
==Honors and awards==
[[File:Crafoordpriset 2009-award ceremony 22.jpg|thumb|Kishimoto receives the Crafoord-Prize]]
[[File:Crafoordpriset 2009-award ceremony 22.jpg|thumb|Kishimoto receives the [[Crafoord Prize]]]]

⚫
*Behring-Kitasato Prize from the [[Hoechst AG|Hoechst Japan]], 1982
===Awards===
{{div col|colwidth=35em}}
⚫
*Behring-Kitasato Prize from [[Hoechst AG|Hoechst Japan]], 1982
*Osaka Science Prize, 1983
*Osaka Science Prize, 1983
*Erwin von Bälz Prize, 1986
*Erwin von Bälz Prize, 1986
*Takeda Prize, 1988
*Takeda Prize, 1988
*Asahi Prize, 1988
*[[Asahi Prize]], 1988
*Prize of The Japanese Medical Association, 1990
*Prize of The Japanese Medical Association, 1990
*Scientific Achievement Award from the International Association of Allergology and Clinical Immunology, 1991
⚫
*[[Imperial Prize of the Japan Academy]], 1992
⚫
*[[Novartis Prize for Clinical Immunology|Sandoz Prize for Immunology]] from International Union of Immunology Society, 1992
⚫
*The Avery-Landsteiner Prize from the German Immunology Society, 1996
⚫
*The Donald Seldin Award from the International Society of Nephrology, 1999
⚫
*[[Thomson Reuters Citation Laureates|ISI Citation Laureate Award]], 2000
⚫
*[[Robert Koch Prize]] - Robert Koch Gold Medal, 2003
⚫
*Honorary Lifetime Achievement Awards, International Cytokine Society, 2006
⚫
*7th International Award of the Japan Rheumatism Foundation, 2008
⚫
*The [[Crafoord Prize]] from the Royal Swedish Academy of Sciences, 2009
⚫
*[[Japan Prize]], 2011
*[[King Faisal International Prize]], 2017
*[[Tang Prize]] in Biopharmaceutical Science, 2020
*[[Clarivate Citation Laureates]], 2021
{{div col end}}

⚫
===Honors===
{{div col|colwidth=35em}}
*[[Person of Cultural Merit]], Japan 1990
*[[Person of Cultural Merit]], Japan 1990
*Foreign Associate, The US National Academy of Science, 1991
*Foreign Associate, The US [[National Academy of Sciences]], 1991
*Scientific Achievement Award from the International Association of Allergology and Clinical Immunology, 1991
*Honorary Member, the [[American Association of Immunologists]], 1992
*Honorary Member, the American Association of Immunologists, 1992
⚫
*Imperial Prize from the Japan Academy, 1992
⚫
*Sandoz Prize for Immunology from International Union of Immunology Society, 1992
*Honorary Citizen, Tondabayashi City, 1992
*Honorary Citizen, Tondabayashi City, 1992
*Member, the Japan Academy, 1995
*Member, the [[Japan Academy]], 1995
⚫
*The Avery-Landsteiner Prize from the German Immunology Society, 1996
*Foreign Associate member, the Institute of Medicine of the National Academy of Science, USA, 1997
*Foreign Associate member, the Institute of Medicine of the National Academy of Science, USA, 1997
*Honorary member, the American Society of Hematology,1997
*Honorary member, the American Society of Hematology, 1997
*The [[Order of Culture]] of Japan, 1998
*The [[Order of Culture]] of Japan, 1998
⚫
*The Donald Seldin Award from the International Society of Nephrology, 1999
⚫
*[[Thomson Reuters Citation Laureates|ISI Citation Laureate Award]], 2000
*Doctor Honoris Causa, Universidad Technologica de Santiago, UTESA, 2001
*Doctor Honoris Causa, Universidad Technologica de Santiago, UTESA, 2001
*Honorary Member, International Association of Dental Research, 2001
*Honorary Member, International Association of Dental Research, 2001
*Honorary Professor, the fourth Military Medical University, Xi’an, China, 2002
*Honorary Professor, the [[Fourth Military Medical University]], Xi’an, China, 2002
*Honorary Member, World Innovation Foundation, 2002
*Honorary Member, World Innovation Foundation, 2002
*Doctor of Science, Honoris Causa, Mahidol University, 2003
*Doctor of Science, Honoris Causa, Mahidol University, 2003
⚫
*Robert Koch Gold Medal, 2003
*Clemens von Pirquet Distinguished Professor, Medicine and Immunology, University California, Davis, 2004
*Clemens von Pirquet Distinguished Professor, Medicine and Immunology, University California, Davis, 2004
*Member, Deutsche Akademie der Naturforscher Leopoldina, 2005
*Member, [[German Academy of Sciences Leopoldina]], 2005
{{div col end}}
⚫
*Honorary Lifetime Achievement Awards, International Cytokine Society, 2006
⚫
*7th International Award of the Japan Rheumatism Foundation, 2008
⚫
*The Crafoord Prize from the Royal Swedish Academy of Sciences, 2009
⚫
*[[Japan Prize]], 2011


==References==
==References==
{{Reflist}}
{{Reflist}}
{{Japan Prize}}

{{Tang Prize winners}}
{{Presidents of Osaka University}}
{{Presidents of Osaka University}}

{{Authority control}}
{{Authority control}}


{{Persondata <!-- Metadata: see [[Wikipedia:Persondata]]. -->
| NAME =Kishimoto, Tadamitsu
| ALTERNATIVE NAMES =
| SHORT DESCRIPTION = Japanese immunologist
| DATE OF BIRTH = 1939
| PLACE OF BIRTH = [[Osaka]]
| DATE OF DEATH =
| PLACE OF DEATH =
}}
{{DEFAULTSORT:Kishimoto, Tadamitsu}}
{{DEFAULTSORT:Kishimoto, Tadamitsu}}
[[Category:Japanese physicians]]
[[Category:Japanese immunologists]]
[[Category:Japanese immunologists]]
[[Category:1939 births]]
[[Category:1939 births]]
[[Category:Living people]]
[[Category:Living people]]
[[Category:People from Osaka Prefecture]]
[[Category:People from Tondabayashi, Osaka]]
[[Category:Members of the United States National Academy of Sciences]]
[[Category:Foreign associates of the National Academy of Sciences]]
[[Category:Recipients of the Order of Culture]]
[[Category:Recipients of the Order of Culture]]
[[Category:Osaka University alumni]]
[[Category:Osaka University alumni]]
[[Category:Osaka University faculty]]
[[Category:Academic staff of Osaka University]]
[[Category:Japan Prize laureates]]
[[Category:Laureates of the Imperial Prize]]
[[Category:Laureates of the Imperial Prize]]
[[Category:Members of the German National Academy of Sciences Leopoldina]]
[[Category:Members of the National Academy of Medicine]]

Latest revision as of 08:36, 30 August 2024

Tadamitsu Kishimoto
Born(1939-05-07)May 7, 1939 (age 84)
Tondabayashi, Osaka, Japan
Nationality Japan
Alma materOsaka University
AwardsAsahi Prize (1988)
Imperial Prize of the Japan Academy (1992)
Order of Culture (1998)
Robert Koch Gold Medal (2003)
Crafoord Prize (2009)
King Faisal International Prize(2017)
Tang Prize (2020)
Scientific career
FieldsBiology

Tadamitsu Kishimoto (岸本 忠三, Kishimoto Tadamitsu, born May 7, 1939 in Tondabayashi, Osaka) is a Japanese immunologist known for research on IgM and cytokines, most famously, interleukin 6.

He did postdoctoral work under Kimishige Ishizaka, the discoverer of IgE at Johns Hopkins University.

He is listed by the Institute for Scientific Information (ISI) as a highly cited biologist and he is also in the top ten of h-index of living biologists.

Life

[edit]

Tadamitsu Kishimoto, who was born in Osaka in 1939, was President of Osaka University from 1997 to 2003 and a Member, Council for Science and Technology Policy, Cabinet office from 2004 to 2006. He is now Professor, Graduate School of Frontier Biosciences, Osaka University. He was Dean, Professor and Chairman of Department of Medicine at Osaka University Medical School from which he graduated in 1964.[1] He is currently Japan's leading scientist in the field of life science, specifically in immunology and has made fundamental contributions to the understanding of cytokine functions through series of his studies on IL-6, its receptor system, and transcription factors. He has developed anti-IL6 receptor therapy for several immune disorders including Castleman's disease, rheumatoid arthritis and juvenile idiopathic arthritis.

He has received numerous awards, including the Imperial Prize of the Japan Academy in 1992,[1] the Sandoz Prize for Immunology from the International Union of Immunological Society in 1992[1] and the Avery-Landsteiner Prize from the German Immunology Society in 1996.[1] In 1998, he was awarded the Order of Culture from Emperor.[1] He was awarded Robert Koch Gold Medal in 2003,[1] Honorary Life Time Achievement Awards from International Cytokine Society in 2006[1] and the Crafoord Award from the Royal Swedish Academy of Sciences in 2009.[1] He has been elected a Foreign Associate of the US National Academy of Sciences in 1991,[1] a member of the Japan Academy in 1995[1] and a member of German Academy of Sciences Leopoldina in 2005.[1] He served as a president of the International Immunopharmacology Society, International Cytokine Society and the Japanese Immunology Society. He is an honorary member in American Association of Immunologists and American Society of Hematology. In 2020, He received the prestigious Tang Prize in Biopharmaceutical Science.

IL-6

[edit]

In the early 1970s, Kishimoto discovered the activity inducing antibody production in culture supernatants of T cells. Furthermore, he demonstrated that the activity for inducing IgG and IgE antibodies could be separated.[2] Later, this finding led to the discovery of the dichotomy of helper T cells, Th1 and Th2. On the basis of these early studies, Kishimoto discovered and cloned interleukin-6 and its receptor and delineated the signaling pathway used by IL-6 and the set of related cytokines that utilize gp-130, which he also discovered.[3][4][5][6] He identified the transcription factors NF-IL-6 and STAT3, both central to the action of IL-6.[7] He further discovered a family of suppressors of cytokine signaling, the SOCS molecules, that are key regulators of cytokine function.[8] He demonstrated the involvement of IL-6 in the pathogenesis of cardiac myxomas, multiple myeloma, Castleman’s disease, rheumatoid arthritis, Crohn's disease and juvenile idiopathic arthritis (JIA). He identified IL-6 as a hepatocyte stimulating factor which induces acute phase reactions. He prepared a monoclonal anti-IL-6 receptor antibody that was subsequently humanized and has been shown to be of great therapeutic value in a series of autoinflammatory diseases including Castleman's Disease, rheumatoid arthritis and juvenile idiopathic arthritis.[9] His work has dominated the field of proinflammatory cytokines and has established paradigms for the study of all of cytokine biology, ranging from discovery of the cytokine and its receptor, through signaling and transcriptional mechanisms, to the utilization of such knowledge to develop highly effective therapeutics.[10] A series of his IL-6 studies for 35 years since 1973 have been highly appreciated; He was ranked as the world’s 8th-most-cited researchers between 1983 and 2002 and he is in the top ten of h-index of living biologists.

Recognition

[edit]
Kishimoto receives the Crafoord Prize

Awards

[edit]

Honors

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k http://www.japanprize.jp/en/prize_prof_2011_kishimoto.html, The Japan Prize Foundation
  2. ^ Kishimoto, T., and K. Ishizaka. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194-1205, 1973.
  3. ^ Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.
  4. ^ Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.
  5. ^ Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. Cloning and expression of human interleukin 6 (BSF-2/IFNb2) receptor. Science 241:825-828, 1988.
  6. ^ Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.
  7. ^ Akira, S., Y.Nishio, M.Inoue, X.Wang, S.Wei, T.Matsusaka, K.Yoshida, T.Sudo, M.Naruto, and T.Kishimoto. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.
  8. ^ Naka, T., M. Narazaki, M.Hirata, T.Matsumoto, S.Minamoto, A.Aono, N.Nishimoto, T.Kajita, T.Taga, K.Yoshizaki, S.Akira, and T.Kishimoto. Structure and function of a new STAT-induced STAT inhibitor-1. Nature 387:924-929, 1997.
  9. ^ Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, T. Kishimoto. Efficary and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008
  10. ^ Kishimoto, T. Interleukin-6: From basic science to medicine, 40 years in immunology. Annu. Rev. Immunol. 23:1-21, 2005.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tadamitsu_Kishimoto&oldid=1243063460"